Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, has received patents corresponding to three new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.
The patents, valid up to 2022, 2023 and 2024 respectively, were granted by the European Patent Office (EPO). With these new patents, Suven now has 7 granted EPO patents on NCEs, which have been validated in the 37 member countries in
The newly granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-generative disorders like Alzheimer’s, Parkinson, schizophrenia, Huntington’s disease and attention-deficit hyperactivity disorder (ADHD). Suven Life currently has six internally-discovered therapeutic drug candidates, which are in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression and Huntington’s disease.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1683.60 |
| Dr. Reddys Lab | 1219.00 |
| Cipla | 1224.30 |
| Zydus Lifesciences | 935.55 |
| Lupin | 2350.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: